In a significant development, India’s top drug regulator has given nod to two domestic pharmaceutical companies--Cipla and Hetero for marketing authorization of anti-viral drug Remdesivir only for “restricted emergency use” on Covid-19 patients with moderate disease (those on oxygen), a senior government official told ANI.
With this development, India is soon to begin the domestic production of anti-viral drug remdesivir which would have efficacy, stability, safety for “restricted emergency use” on Covid-19 patients, official added.
